Denali Therapeutics (DNLI) Short Interest Ratio & Short Volume $25.05 -3.40 (-11.95%) (As of 11/15/2024 ET) Add Compare Share Share Short Interest Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Denali Therapeutics Short Interest DataDenali Therapeutics (DNLI) has a short interest of 7.43 million shares, representing 5.93% of the float (the number of shares available for trading by the public). This marks a -3.88% decrease in short interest from the previous month. The short interest ratio (days to cover) is 8.9, indicating that it would take 8.9 days of the average trading volume of 1.07 million shares to cover all short positions.Current Short Interest7,430,000 sharesPrevious Short Interest7,730,000 sharesChange Vs. Previous Month-3.88%Dollar Volume Sold Short$192.88 millionShort Interest Ratio8.9 Days to CoverLast Record DateOctober 31, 2024Outstanding Shares143,920,000 sharesFloat Size125,370,000 sharesShort Percent of Float5.93%Today's Trading Volume1,103,219 sharesAverage Trading Volume1,070,498 sharesToday's Volume Vs. Average103% Short Selling Denali Therapeutics? Sign up to receive the latest short interest report for Denali Therapeutics and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartDNLI Short Interest Over TimeDNLI Days to Cover Over TimeDNLI Percentage of Float Shorted Over Time Ad Insiders ExposedHas Trump Finally Gone Too Far?Lately, there's been a lot of buzz around a secret loophole executive insiders are using to make millions buying and selling their own stocks. It's so powerful ... so profitable ... that most people immediately assume this is just another example of Trump doing what's best for business executives. But surprisingly, this loophole has been on the books for many years and executives have been using it to make HUNDREDS of millions of dollars. And here's the good news.Register For The Webinar To Discover Denali Therapeutics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 10/31/20247,430,000 shares $192.88 million -3.9%5.9%8.9 $25.96 10/15/20247,730,000 shares $207.55 million -0.1%6.5%9 $26.85 9/30/20247,740,000 shares $225.47 million -17.7%6.5%8.1 $29.13 9/15/20249,400,000 shares $289.24 million +4.3%7.9%9 $30.77 8/31/20249,010,000 shares $220.20 million +7.8%7.6%8.2 $24.44 8/15/20248,360,000 shares $197.88 million +16.3%7.0%7.3 $23.67 Get the Latest News and Ratings for DNLI and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Denali Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 7/31/20247,190,000 shares $175.22 million +1.4%6.1%6.1 $24.37 7/15/20247,090,000 shares $165.41 million -4.6%6.1%5.8 $23.33 6/30/20247,430,000 shares $172.52 million -16.1%6.3%6.1 $23.22 6/15/20248,860,000 shares $183.67 million -5.0%7.6%7.7 $20.73 5/31/20249,330,000 shares $173.16 million -1.7%8.0%8.6 $18.56 5/15/20249,490,000 shares $197.96 million -9.6%8.1%8 $20.86 4/30/202410,500,000 shares $162.12 million +9.6%8.2%8.3 $15.44 4/15/20249,580,000 shares $170.91 million +1.8%8.3%7.9 $17.84 3/31/20249,410,000 shares $193.09 million +12.3%8.4%8 $20.52 3/15/20248,380,000 shares $168.69 million -5.5%7.5%7.2 $20.13 2/29/20248,870,000 shares $175.45 million -18.0%7.9%7.3 $19.78 2/15/202410,820,000 shares $198.66 million +10.0%9.7%9.5 $18.36 1/31/20249,840,000 shares $157.54 million -0.4%9.0%9.4 $16.01 1/15/20249,880,000 shares $183.18 million +2.6%8.7%9.5 $18.54 12/31/20239,630,000 shares $206.66 million +5.4%8.5%9.7 $21.46 12/15/20239,140,000 shares $209.67 million +0.2%8.0%9.2 $22.94 11/30/20239,120,000 shares $168.90 million -4.6%8.0%10.1 $18.52 11/15/20239,560,000 shares $176.67 million -10.9%8.4%11.2 $18.48 10/31/202310,730,000 shares $202.05 million +12.7%9.5%13.9 $18.83 10/15/20239,520,000 shares $197.64 million -2.0%8.8%13.7 $20.76 9/30/20239,710,000 shares $200.32 million +3.6%8.9%15.1 $20.63 9/15/20239,370,000 shares $220.66 million +3.1%8.6%15.4 $23.55 8/31/20239,090,000 shares $209.89 million -1.5%8.3%14 $23.09 8/15/20239,230,000 shares $224.20 million +6.2%8.5%13.9 $24.29 7/31/20238,690,000 shares $247.06 million +6.4%8.1%12.6 $28.43 7/15/20238,170,000 shares $239.63 million +1.4%7.7%11.4 $29.33 6/30/20238,060,000 shares $237.85 million -7.7%7.5%10.5 $29.51 6/15/20238,730,000 shares $283.64 million +8.0%8.2%11.1 $32.49 5/31/20238,080,000 shares $244.18 million -6.4%7.6%10.8 $30.22 5/15/20238,630,000 shares $276.33 million No Change8.1%11.4 $32.02 10/31/20226,980,000 shares $200.19 million -4.3%6.2%8.4 $28.68 10/15/20227,290,000 shares $237.44 million +2.7%6.6%9 $32.57 9/30/20227,100,000 shares $217.90 million +6.6%7.0%10.5 $30.69 9/15/20226,660,000 shares $207.06 million +0.2%6.5%10.5 $31.09Has Trump Finally Gone Too Far? (Ad)Lately, there's been a lot of buzz around a secret loophole executive insiders are using to make millions buying and selling their own stocks. It's so powerful ... so profitable ... that most people immediately assume this is just another example of Trump doing what's best for business executives. But surprisingly, this loophole has been on the books for many years and executives have been using it to make HUNDREDS of millions of dollars. And here's the good news.Register For The Webinar To Discover 8/31/20226,650,000 shares $184.01 million +2.0%6.5%9.9 $27.67 8/15/20226,520,000 shares $245.22 million -11.5%6.4%10.4 $37.61 7/31/20227,370,000 shares $250.73 million -2.5%7.6%11.2 $34.02 7/15/20227,560,000 shares $262.33 million -0.4%7.8%12 $34.70 6/30/20227,590,000 shares $223.37 million -3.2%7.8%12.5 $29.43 6/15/20227,840,000 shares $177.03 million +0.5%8.1%13.4 $22.58 5/31/20227,800,000 shares $189.46 million +5.4%8.0%14.7 $24.29 5/15/20227,400,000 shares $169.16 million +11.1%7.6%13.7 $22.86 4/30/20226,660,000 shares $158.51 million +1.1%6.9%12.8 $23.80 4/15/20226,590,000 shares $198.42 million -2.2%6.8%12.9 $30.11 3/31/20226,740,000 shares $216.83 million +0.2%N/A11.5 $32.17 3/15/20226,730,000 shares $199.28 million +3.5%6.9%11.5 $29.61 2/28/20226,500,000 shares $211.64 million -2.1%7.8%11.1 $32.56 2/15/20226,640,000 shares $236.65 million +20.7%8.0%11.3 $35.64 1/31/20225,500,000 shares $188.21 million +1.7%6.7%9.6 $34.22 1/15/20225,410,000 shares $188.48 million +2.3%6.6%10 $34.84 12/31/20215,290,000 shares $235.93 million -7.5%6.5%11.2 $44.60 12/15/20215,720,000 shares $260.32 million +9.8%7.0%11.7 $45.51 11/30/20215,210,000 shares $241.01 million -4.6%6.4%10.4 $46.26 11/15/20215,460,000 shares $273.66 million -3.4%6.7%11.3 $50.12 10/29/20215,650,000 shares $273.18 million -6.6%6.9%12.1 $48.35 10/15/20216,050,000 shares $275.64 million -6.2%7.4%12.8 $45.56 9/30/20216,450,000 shares $325.40 million +10.6%7.8%12.2 $50.45 9/15/20215,830,000 shares $306.83 million +1.0%7.1%9.9 $52.63 8/31/20215,770,000 shares $306.96 million +1.2%7.0%10.1 $53.20 8/13/20215,700,000 shares $300.56 million +3.8%6.9%8.8 $52.73 7/30/20215,490,000 shares $280.15 million +7.0%6.7%8.3 $51.03 7/15/20215,130,000 shares $329.45 million -6.9%6.1%7.9 $64.22 6/30/20215,510,000 shares $432.20 million +2.0%6.5%9 $78.44 6/15/20215,400,000 shares $397.33 million -5.4%6.4%10.2 $73.58 5/28/20215,710,000 shares $363.10 million -3.4%6.8%11.3 $63.59 5/14/20215,910,000 shares $305.55 million -4.1%7.1%11.1 $51.70 4/30/20216,160,000 shares $377.73 million -4.9%7.5%11.4 $61.32 4/15/20216,480,000 shares $358.21 million -1.7%N/A12 $55.28 3/31/20216,590,000 shares $357.24 million -1.2%8.1%11.7 $54.21 3/15/20216,670,000 shares $431.48 million -0.5%8.2%10.3 $64.69 2/26/20216,700,000 shares $422.10 million -3.9%8.3%9.8 $63.00 2/12/20216,970,000 shares $484.76 million -1.4%8.7%10.5 $69.55 1/29/20217,070,000 shares $500.98 million -4.2%9.3%10 $70.86 1/15/20217,380,000 shares $546.05 million -8.6%9.7%10 $73.99 12/31/20208,070,000 shares $691.20 million -6.2%10.7%11.1 $85.65 12/15/20208,600,000 shares $707.52 million +0.7%11.4%12.6 $82.27 11/30/20208,540,000 shares $523.25 million -5.1%11.3%12.5 $61.27 11/15/20209,000,000 shares $586.53 million -1.8%11.9%13.9 $65.17 10/30/20209,160,000 shares $417.33 million -4.7%12.5%14.5 $45.56 10/15/20209,610,000 shares $418.13 million +5.3%14.3%13.8 $43.51 9/30/20209,130,000 shares $327.13 million -1.2%12.5%13.2 $35.83 9/15/20209,240,000 shares $344.37 million +3.1%12.7%13.1 $37.27 8/31/20208,960,000 shares $285.82 million +1.7%12.3%12.6 $31.90 8/14/20208,810,000 shares $269.94 million -11.1%12.1%12.4 $30.64The Tesla Trade Is Back In Business (Ad)If you held shares of Tesla throughout 2024, you know It’s been a year of extreme highs and lows… But according to our one expert, new yearly highs are on the horizon… In his words, Tesla is building momentum like in 2020, especially as Trump supports the EV maker. Which is why we’re emailing you now… You see, most people will simply buy shares of Tesla ahead of the election… But as they say “There is more than one way to skin a cat” In fact, we’ve found another way to play shares of Tesla.Discover how to trade Tesla, simply follow this link here. 7/31/20209,910,000 shares $232.09 million +0.6%13.6%15.4 $23.42 7/15/20209,850,000 shares $254.13 million -11.3%13.6%18.9 $25.80 6/30/202011,110,000 shares $263.31 million +14.3%15.3%22 $23.70 6/15/20209,720,000 shares $249.42 million +6.0%13.4%20.1 $25.66 5/29/20209,170,000 shares $255.20 million +2.3%12.7%18.7 $27.83 5/15/20208,960,000 shares $206.71 million -0.6%12.4%16.7 $23.07 4/30/20209,010,000 shares $209.30 million -1.7%12.5%16.8 $23.23 4/15/20209,170,000 shares $183.49 million +2.9%12.7%13.3 $20.01 3/31/20208,910,000 shares $202.88 million -5.9%12.4%11.8 $22.77 3/13/20209,469,800 shares $185.23 million -8.4%13.2%14.9 $19.56 2/28/202010,340,000 shares $173.20 million +0.9%14.4%16.2 $16.75 2/14/202010,250,000 shares $184.40 million -2.8%14.4%17.9 $17.99 1/31/202010,540,000 shares $227.98 million +6.7%15.4%19.2 $21.63 1/15/20209,880,000 shares $242.95 million +3.8%15.8%22.5 $24.59 12/31/20199,520,000 shares $234.67 million -3.0%15.2%26.6 $24.65 DNLI Short Interest - Frequently Asked Questions What is Denali Therapeutics' current short interest? Short interest is the volume of Denali Therapeutics shares that have been sold short but have not yet been closed out or covered. As of October 31st, traders have sold 7,430,000 shares of DNLI short. 5.93% of Denali Therapeutics' shares are currently sold short. Learn More on Denali Therapeutics' current short interest. What is a good short interest ratio for Denali Therapeutics? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. DNLI shares currently have a short interest ratio of 9.0. Learn More on Denali Therapeutics's short interest ratio. Which institutional investors are shorting Denali Therapeutics? As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Denali Therapeutics: Jane Street Group LLC. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission. What is a good short interest percentage for Denali Therapeutics? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 5.93% of Denali Therapeutics' floating shares are currently sold short. Is Denali Therapeutics' short interest increasing or decreasing? Denali Therapeutics saw a decrease in short interest during the month of October. As of October 31st, there was short interest totaling 7,430,000 shares, a decrease of 3.9% from the previous total of 7,730,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. What is Denali Therapeutics' float size? Denali Therapeutics currently has issued a total of 143,920,000 shares. Some of Denali Therapeutics' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Denali Therapeutics currently has a public float of 125,370,000 shares. How does Denali Therapeutics' short interest compare to its competitors? 5.93% of Denali Therapeutics' shares are currently sold short. Here is how the short interest of companies in the sector of "medical" compare to Denali Therapeutics: Cytokinetics, Incorporated (13.75%), Prothena Co. plc (13.99%), REGENXBIO Inc. (9.91%), BioMarin Pharmaceutical Inc. (2.82%), Vaxcyte, Inc. (7.16%), Neurocrine Biosciences, Inc. (2.45%), Bio-Techne Co. (2.00%), Exelixis, Inc. (3.28%), Revolution Medicines, Inc. (10.78%), Qiagen (1.61%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: Charter Communications, Inc. ($4.08 billion), AppLovin Co. ($3.18 billion), Paychex, Inc. ($2.64 billion), Nu Holdings Ltd. ($2.54 billion), International Paper ($2.46 billion), Cencora, Inc. ($2.27 billion), Moderna, Inc. ($1.87 billion), SoFi Technologies, Inc. ($1.81 billion), Lululemon Athletica Inc. ($1.75 billion), and Onsemi ($1.71 billion). View all of the most shorted stocks. What does it mean to sell short Denali Therapeutics stock? Short selling DNLI is an investing strategy that aims to generate trading profit from Denali Therapeutics as its price is falling. DNLI shares are trading down $3.40 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Denali Therapeutics? A short squeeze for Denali Therapeutics occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of DNLI, which in turn drives the price of the stock up even further. How often is Denali Therapeutics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including DNLI, twice per month. The most recent reporting period available is October, 31 2024. More Short Interest Resources from MarketBeat Related Companies Cytokinetics Short Squeeze Prothena Short Squeeze REGENXBIO Short Squeeze BioMarin Pharmaceutical Short Squeeze Vaxcyte Short Squeeze Neurocrine Biosciences Short Squeeze Bio-Techne Short Squeeze Exelixis Short Squeeze Revolution Medicines Short Squeeze Qiagen Short Squeeze Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:DNLI) was last updated on 11/17/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredThere is a little known company that is changing warfareWith geo - political instability around the world investors are flocking to defense contract stocks. There...Reticulate | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Denali Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Denali Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
